Efficacy and Safety of Transarterial Chemoembolization and Repeated Partial Splenic Embolization for Hepatocellular Carcinoma with Hypersplenism and Thrombocytopenia

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Boyer TD, Habib S. Big spleens and hypersplenism: fix it or forget it? Liver Int. 2015;35:1492–1498. doi:10.1111/liv.12702
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017;37:778–793. doi:10.1111/liv.13317
   PubMed Web of Science ®Google Scholar
• Ahuja C, Farsad K, Chadha M. An overview of splenic embolization. AJR Am J Roentgenol. 2015;205:720–725. doi:10.2214/AJR.15.14637
   PubMed Web of Science ®Google Scholar
• Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the English language literature. J Vasc Interv Radiol. 2007;18:463–481. doi:10.1016/j.jvir.2006.12.734
   PubMed Web of Science ®Google Scholar
• Huang Y, Ren D, Gao F, et al. An updated meta-analysis of partial splenic embolization versus splenectomy in the treatment of hypersplenism due to cirrhosis. Minim Invasive Ther Allied Technol. 2022;31:664–675. doi:10.1080/13645706.2021.1933535
   PubMed Web of Science ®Google Scholar
• Cai M, Huang W, Lin C, et al. Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications. Eur Radiol. 2016;26:370–380. doi:10.1007/s00330-015-3839-4
   PubMed Web of Science ®Google Scholar
• Talwar A, Gabr A, Riaz A, et al. Adverse events related to partial splenic embolization for the treatment of hypersplenism: a systematic review. J Vasc Interv Radiol. 2020;31:1118–1131 e1116. doi:10.1016/j.jvir.2019.08.015
   PubMed Web of Science ®Google Scholar
• Tan Y, Wang J, Sun L, Ye Y. Repeated partial splenic artery embolization for hypersplenism improves platelet count. Open Med. 2022;17:808–815. doi:10.1515/med-2022-0479
   Web of Science ®Google Scholar
• Hill A, Elakkad A, Kuban J, et al. Durability of partial splenic artery embolization on platelet counts for cancer patients with hypersplenism-related thrombocytopenia. Abdom Radiol. 2020;45:2886–2894. doi:10.1007/s00261-020-02523-5
   PubMed Web of Science ®Google Scholar
• Huang JH, Gao F, Gu YK, Li WQ, Lu LW. Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterol. 2007;13:6593–6597. doi:10.3748/wjg.v13.i48.6593
   PubMed Web of Science ®Google Scholar
• Ooka Y, Chiba T, Ogasawara S, et al. Partial splenic embolization with transarterial chemoembolization in patients with hepatocellular carcinoma accompanied by thrombocytopenia. Biomed Res Int. 2014;2014:960628. doi:10.1155/2014/960628
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Kubota T, Horigome R, et al. Concurrent partial splenic embolization with transcatheter arterial chemoembolization for hepatocellular carcinoma can maintain hepatic functional reserve. Hepatol Res. 2014;44:1056–1061. doi:10.1111/hepr.12222
   PubMed Web of Science ®Google Scholar
• Kim NH, Kim HJ, Cho YK, Hong HP, Kim BI. Long-term efficacy and safety of partial splenic embolization in hepatocellular carcinoma patients with thrombocytopenia who underwent transarterial chemoembolization. J Korean Med Sci. 2019;34:e208. doi:10.3346/jkms.2019.34.e208
   PubMed Web of Science ®Google Scholar
• Han MJ, Zhao H-G, Ren K, et al. Partial splenic embolization for hypersplenism concomitant with or after arterial embolization of hepatocellular carcinoma in 30 patients. Cardiovasc Intervent Radiol. 1997;20:125–127. doi:10.1007/s002709900119
   PubMed Web of Science ®Google Scholar
• Liu J, Wu Z, Zhang J, et al. Effect of partial splenic embolization on transarterial chemoembolization for hepatocellular carcinoma with hypersplenism. Medicine. 2021;100:e26441. doi:10.1097/MD.0000000000026441
   PubMed Web of Science ®Google Scholar
• Zhou J, Feng Z, Liu S, et al. Simultaneous CSM-TACE with CalliSpheres((R)) and partial splenic embolization using 8spheres((R)) for hepatocellular carcinoma with hypersplenism: early prospective multicenter clinical outcome. Front Oncol. 2022;12:998500. doi:10.3389/fonc.2022.998500
   PubMed Web of Science ®Google Scholar
• Liang B, Xiang H, Ma C, et al. Comparison of chemoembolization with CalliSpheres((R)) microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study. Cancer Manag Res. 2020;12:941–956. doi:10.2147/CMAR.S187203
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• Matsukiyo Y, Nagai H, Matsui T, Igarashi Y. Host immunological effects of partial splenic embolization in patients with liver cirrhosis. J Immunol Res. 2018;2018:1746391. doi:10.1155/2018/1746391
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015:S185–S198. doi:10.1016/j.semcancer.2015.03.004
   PubMed Web of Science ®Google Scholar
• Wu L, Yang F-R, Xing M-L, et al. Multi-material basis and multi-mechanisms of the Dahuang Zhechong pill for regulating Treg/Th1 balance in hepatocellular carcinoma. Phytomedicine. 2022;100:154055. doi:10.1016/j.phymed.2022.154055
   PubMed Web of Science ®Google Scholar